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Background: Aberrant global DNA methylation is shown to increase cancer risk. LINE-1 has been proven a measure of global
DNA methylation. The objectives of this study were to assess the association between LINE-1 methylation level and bladder
cancer risk and to evaluate effect modification by environmental and genetic factors.
Methods: Bisulphite-treated leukocyte DNA from 952 cases and 892 hospital controls was used to measure LINE-1 methylation
level at four CpG sites by pyrosequencing. Logistic regression model was fitted to estimate odds ratios (ORs) and 95% confidence
intervals (95% CIs). Interactions between LINE-1 methylation levels and environmental and genetic factors were assessed.
Results: The risk of bladder cancer followed a nonlinear association with LINE-1 methylation. Compared with subjects in the
middle tertile, the adjusted OR for subjects in the lower and the higher tertiles were 1.26 (95% CI 0.99–1.60, P¼ 0.06) and 1.33 (95% CI
1.05–1.69, P¼ 0.02), respectively. This association significantly increased among individuals homozygous for the major allele of five
single-nucleotide polymorphisms located in the phosphatidylethanolamine N-methyltransferase gene (corrected P-interactiono0.05).
Conclusions: The findings from this large-scale study suggest that both low and high levels of global DNA methylation are
associated with the risk of bladder cancer.
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Bladder cancer is one of the most common cancers in the
developed countries mainly affecting men (Parkin, 2008). In Spain,
the incidence rate of bladder cancer has been increasing in the past
three decades and the ratio of men to women developing the
disease is 7 : 1 (Izarzugaza et al, 2010). Recurrence is a major
problem in the management of bladder cancer necessitating
frequent follow-ups, thus making it one of the most expensive
cancer types to treat (Lotan et al, 2008). Established risk factors for
bladder cancer include tobacco smoking, occupational exposures to
aromatic amines, arsenic in drinking water (Murta-Nascimento
et al, 2007; Volanis et al, 2010) and genetic variants of NAT2 and
GSTM1; the latter two have been shown to significantly modify the
risk conferred by tobacco smoking (Garcia-Closas et al, 2005;
Rothman et al, 2010). Recently, additional common genetic
variants on CBX6-APOBEC3A, CCNE1, MYC, PSCA, SLC14A1,
TERT-CLPTM1L, TMEM129-TACC-FGFR3, TP63 and UGT1A
cluster have been associated with risk of bladder cancer (Rothman
et al, 2010; Garcia-Closas et al, 2011).
Genome-wide altered epigenetic states are common findings in
several malignancies, including bladder tumours. These epigenetic
states include global DNA hypomethylation and gene promoter
methylation, post-translational histone modifications and deregulation
of microRNAs (Esteller, 2008; Taby and Issa, 2010). Global
DNA hypomethylation in cancer is mostly found in repetitive
sequences of the genome such as long interspersed nuclear element
1 (LINE-1) and Alu elements (Esteller, 2008). It has been suggested
that methylation represses the transcription of these repetitive
regions to maintain genomic stability and prevent mutations,
deletions and insertions (Esteller, 2008). In bladder cancer,
genomic instability has been observed at different stages of the
disease (Florl and Schulz, 2008). There is evidence that LINE-1
hypomethylation could also induce the expression of the MET
oncogene in bladder cancer and normal tissues (Wolff et al, 2010).
Global DNA methylation measured in peripheral blood cells has
been used to investigate its relationship with cancer risk, although
results have been inconclusive (Woo and Kim, 2012). Studies
investigating the role of genomic DNA methylation (measured by
direct quantification of 5-methylcytosine as well as at CpG sites in
LINE-1 sequences) and bladder cancer have inconclusively shown
an inverse association between genomic DNA methylation and risk
of bladder cancer (Moore et al, 2008; Wilhelm et al, 2010; Cash
et al, 2012). Whether environmental and genetic factors modify the
association between global DNA methylation and bladder cancer
risk is not known, although it has been suggested that smoking, B
vitamins, arsenic and genes involved in the one-carbon metabolism
pathway may have a modifier role (Moore et al, 2007; Volanis et al,
2010). Hence, understanding the role of global DNA methylation
in bladder cancer development and its interaction with other
known and potential risk factors may provide further insight on
the aetiology and susceptibility of this tumour.
The objectives of this study were to assess the risk of bladder
cancer associated with LINE-1 methylation levels, as a measure of
global DNA methylation in peripheral blood, as well as to explore
whether personal, lifestyle, environmental and genetic factors
modify this association.
MATERIALS AND METHODS
Study population. The Spanish Bladder Cancer/EPICURO Study
is a multi-center, hospital-based case–control study conducted in
five regions of Spain (Barcelona, Valles, Elche, Tenerife and
Asturias) between 1998 and 2001. The design of the study has been
previously described elsewhere in detail (Garcia-Closas et al, 2005;
Samanic et al, 2006). Briefly, cases and controls were recruited to
the study from 18 hospitals. Cases were newly diagnosed subjects
with histologically confirmed urothelial carcinoma of the bladder.
Controls were patients admitted to the same hospital as cases for
reasons not related to exposures of interest and individually
matched for age (±5 years), sex and geographic region to cases.
From the initial study population of 1219 cases and 1271 controls,
1107 cases and 1032 controls provided blood sample (before
treatment was instituted). Of these, 995 cases and 925 controls, all
Caucasians and without missing demographic data, had enough
granulocyte DNA for sodium bisulphite treatment and subsequent
measurement of DNA methylation. Because in 43 cases and 33
controls quantification of DNA methylation failed, the final study
population for the current analysis was 952 cases and 892 controls
aged from 20 to 81 years. Written informed consent was obtained
from each study subject before interview, and the study was
approved by the US National Cancer Institute and local
institutional review boards.
Data on demographic and personal characteristics, smoking and
other known and potential risk factors for bladder cancer were
collected by means of a computer-assisted personal interview. Food
frequency questionnaires were used to collect data on fruit,
vegetable, B vitamins and protein and alcohol intake over the 5
years before interview (Garcia-Closas et al, 2007b).
Analysis of LINE-1 methylation. Bisulphite modification of
genomic DNA extracted from granulocytes using standard
techniques was performed using EZ-96 DNA METHYLATION-
GOLD KIT (Zymo Research, Irvin, CA, USA) following the
recommendations of the manufacturer. PCR amplification of
bisulphite-modified DNA was carried out using a set of forward
and reverse primers reported previously (Estecio et al, 2007). To
quantify the methylation level of each of the four CpG sites
immediately after the sequencing primer, sequencing of the PCR
product was performed by pyrosequencing using PyroMark Q24
System (QIAGEN, Valencia, CA, USA) as recommended by the
manufacturer. Methylation level at each CpG site was extracted
using PyroMark Application Software version 2.0.6 (QIAGEN),
and the value was expressed as the percentage of methylated
cytosines over the sum of methylated and unmethylated cytosines.
The average methylation level of the four LINE-1 CpG sites was
used in the analysis as a marker of the global DNA methylation
level. As a quality control measure, 307 randomly selected samples
from cases and controls were run in duplicate and the within-
sample coefficient of variation was 4.53%. The mean methylation
level of the duplicates was used in the analysis.
Genotyping. Genotyping was carried out using DNA isolated
form granulocytes as described previously (Garcia-Closas et al,
2005). All genotype assays used in this analysis were done at the
Core Genotyping Facility of the Division of Cancer Epidemiology
and Genetics, National Cancer Institute, Bethesda, MD, USA.
Methods of the SNP genotyping process were described previously
(Garcia-Closas et al, 2005, 2007a; Rothman et al, 2010). SNP
genotyping was done using Illumina Infinium Human1M-Duo
(480 SNPs), Illumina GoldenGate (36 SNPs) (Illumina, San Diego,
CA, USA), and TaqMan (8 SNPs) (Applied Biosystems, Foster
City, CA, USA) assays. All genotypes included in the study were in
Hardy–Weinberg equilibrium in the control population (P40.05).
A total of 524 SNPs and copy number variation in GSTM1 and
GSTT1 were assessed in the present study. Of these SNPs, 515
SNPs were located in 24 candidate genes involved in one-carbon
metabolism pathway, including DNA methylation and arsenic
metabolism (Supplementary Table S1). These pathways are known
to influence DNA methylation by altering the cellular concentra-
tion of the methyl group donor S-adenosylmethionine (SAM)
(Ulrey et al, 2005; Moore et al, 2007; Lee et al, 2009). Additionally,
eight SNPs identified in a recent multi-stage genome-wide
association study of bladder cancer and a SNP rs1495741 tagging
NAT2 acetylator phenotype were also included in the analysis
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(Rothman et al, 2010). SNPs and variants were investigated for
their modifier effect on the association between LINE-1 methyla-
tion and bladder cancer risk.
Quantification of trace elements. Methods of quantification of
toenail trace element level included in the current study have been
previously described (Amaral et al, 2011). Briefly, after cleaning
and washing the toenails to remove external contaminants, trace
elements were quantified at the Trace Element Analysis Core
(Dartmouth College, NH, USA), using inductively coupled plasma-
mass spectrometry (Hopkins et al, 2004). Toenails were digested
with Optima nitric acid (Fisher Scientific, St Louis, MO, USA), at
105 1C, then with hydrogen peroxide and further heating the
dilution with deionised water. All sample preparation steps were
recorded gravimetrically. For quality control, each batch of
analyses accommodated six standard reference material samples
with known trace element content (GBW 07601, powdered human
hair) and six analytic blanks, together with the study samples.
Overall, concentrations (mg g 1) of 12 trace elements (aluminum,
arsenic, cadmium, chromium, copper, iron, lead, manganese,
nickel, selenium, vanadium and zinc) were determined.
Statistical analysis. Chi-squared test was used to evaluate the
association between case–control status and categorical variables.
Normality of LINE-1 methylation distribution was assessed
graphically by plotting histograms (Supplementary Figure S1)
and formally tested by using Shapiro–Wilk test for normality.
The non-parametric Mann–Whitney U-test was used to compare
medians of continuous variables in different strata.
To estimate the risk associated with global DNA methylation
and examine nonlinear association, LINE-1 methylation level was
modeled using restricted cubic splines in a logistic regression
model adjusting for age (continuous), sex, region and smoking
status (never, occasional, former and current smoker). Cubic spline
models are polynomial functions that provide examination of a
nonlinear association between a dependent and an explanatory
variable. In the restricted cubic spline regression model, methyla-
tion level of 59% was set as a reference, and four knots
(boundaries) at the 5, 35, 65 and 95 percentiles of LINE-1
methylation level were used to restrict the function to be linear
beyond the boundaries at extreme values of LINE-1 methylation
(Royston and Sauerbrei, 2007). Upon the visualisation of a
nonlinear ‘U-shape’ risk pattern from the cubic spline regression
(Supplementary Figure S2), LINE-1 methylation levels were
categorised into three categories by using tertile cut points
(56.68% and 58.65%) based on its distribution among the control
population. For subsequent analyses, this variable was used by
assigning the middle tertile as the referent category. Unadjusted
and adjusted logistic regression models were fitted to estimate odds
ratios (ORs) and the corresponding 95% confidence intervals (95%
CIs). In addition to LINE-1 methylation, variables included in the
basic multivariable adjusted model were age, sex, region and
smoking status. Association between LINE-1 methylation, in
tertiles, at each of the four LINE-1 CpG sites and risk of bladder
cancer was evaluated. Also, and in order to mimic the distribution
of LINE-1 methylation levels in tertiles using a continuous variable,
the association between the absolute deviation (continuous) from
the median LINE-1 methylation level was modeled by logistic
regression unadjusted and adjusted for age, sex, region and
smoking status. Moreover, the association between LINE-1
methylation and bladder cancer subphenotypes (low-, high-grade
non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive
bladder cancer (MIBC)) was modeled using multinomial logistic
regression. Likelihood ratio test for heterogeneity was used to test
whether the ORs for low-, high-grade NMIBC and MIBC are
different from each other.
Interaction between LINE-1 methylation and individual covari-
ates (age (o60, 60–69, andX70 years), sex, smoking status (never
and ever smoker), dietary factors, trace elements (continuous) and
SNPs (four modes of inheritance)) was tested by including a
multiplicative interaction term into the logistic regression model.
For the interaction between LINE-1 methylation and smoking,
additional analyses included adjustment among regular smokers
for each of the following, as a continuous variable: pack-years,
duration of cigarette smoking, and number of cigarettes smoked
per day. Significance of the interaction term was tested by
comparing the models with and without the interaction term
using the likelihood ratio test. To estimate a corrected multiple
testing interaction P for each SNP, a permutation test done by
randomly sampling 10 000 times was applied by assigning case/
control status in a proportion similar to the current study. All
statistical tests were two-sided, and a Po0.05 was considered
significant. Statistical analyses were carried out by using STATA/SE,
version 10.1 (StataCorp, College Station, TX, USA).
RESULTS
The characteristics of cases and controls are shown in Table 1. Subjects
were mostly men and smokers. A large proportion of cases (78%) were
diagnosed with a NMIBC. The distribution of global DNA
methylation was bimodal. The median (interquartile range) LINE-1
methylation levels among cases and controls were 57.60% (4.06%) and
57.44% (3.36%), respectively (P¼ 0.3). The minimum and maximum
values of LINE-1 methylation were 28.81% and 85.44% among cases
and 37.91% and 85.68% among controls, respectively.
Compared with subjects in the middle tertile of LINE-1
methylation, the adjusted ORs were 1.26 (95% CI 0.99–1.60,
P¼ 0.06) and 1.33 (95% CI 1.05–1.69, P¼ 0.02) for the lowest and
highest tertiles, respectively. These ORs were very similar to the
crude ones (Table 2). The associations between methylation level at
each of the four CpG positions of LINE-1 and risk of bladder
cancer were similar to the results using the average of LINE-1
methylation level (Supplementary Table S2). The association for
the absolute deviation from the median LINE-1 methylation level,
modeled as a continuous variable and adjusted for age, sex, region
and smoking status, was similarly significant (adjusted OR¼ 1.03,
95% CI 1.01–1.05, P¼ 0.008). When further analysis was carried
out separately for low-, high-grade NMIBC and MIBC, ORs for
LINE-1 methylation levels were similar to the overall OR, and no
heterogeneity was found between the three bladder cancer
subphenotypes (P40.05) (Supplementary Table S3).
The effect of LINE-1 on bladder cancer risk was not modified by
age, sex, tobacco type, nutrient intakes or trace elements
(Supplementary Tables S4 and S5). Although the risk of bladder
cancer associated with low and high levels of LINE-1 methylation
was significant among never smokers, the interaction between
LINE-1 methylation and smoking status was not significant
(P¼ 0.2; Supplementary Table S4). This interaction was not
significant even when comparing never smokers with regular
smokers, after adjusting the models for duration of cigarette
smoking, cigarettes smoked per day or pack-years among smokers
(data not shown). There was no interaction between variation in
GSTM1 or GSTT1 or SNPs previously associated with bladder
cancer risk and LINE-1 methylation levels. The same is true for
most of the SNPs in genes from the one-carbon metabolism
pathway (Supplementary Tables S5 and S6). However, the
increased risk of bladder cancer among subjects in the lowest
and highest tertiles was significantly modified by five SNPs
(rs2124344, rs7215833, rs4646340, rs4646350 and rs4646341)
in the phosphatidylethanolamine N-methyltransferase (PEMT)
gene. Under the dominant mode of inheritance, the risk of
bladder cancer being in the lowest or highest tertile of LINE-1
methylation was significantly increased only among individuals
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homozygous for the major allele of each of the five SNPs
(P-interactionp4.9 10 5; P-interactionp0.03 corrected for
multiple testing; Table 3).
DISCUSSION
The current study shows that both low and high levels of LINE-1
methylation are associated with increased risk of bladder cancer
corresponding to a nonlinear – ‘U-shaped’ – association between
global genomic DNA methylation level and bladder cancer risk.
This association was significantly modified by the five SNPs in the
PEMT gene. Altogether, this points to the complex aetiological
mechanisms of DNA methylation in bladder cancer development.
The finding of increased risk of bladder cancer among
individuals with low level of methylation is in agreement with
previous reports (Moore et al, 2008; Wilhelm et al, 2010; Cash et al,
2012). Moore et al (2008), by analyzing global 5-methylcytosine
content of the genome using HpaII, high-performance capillary
electrophoresis and densitometry, showed that low level of global
DNA methylation was associated with increased risk of bladder
cancer in a subsample of the same study. Additionally, two studies
also using sodium bisulphite modification of leukocyte DNA,
followed by pyrosequencing to quantify methylation levels of four
LINE-1 CpG sites, reported a similar inverse association between
LINE-1 methylation level and risk of bladder cancer in
independent populations (Wilhelm et al, 2010; Cash et al, 2012).
An experimental study demonstrated hypomethylation of LINE-1
sequences in urothelial carcinoma cell lines and tumours compared
with normal bladder tissue (Jurgens et al, 1996). Another study
also showed that hypomethylation of LINE-1 promoter can induce
the expression of the MET oncogene in bladder tumours and
normal urothelial tissues (Wolff et al, 2010). Interestingly, the
current study also shows that higher methylation level was
associated with increased risk of bladder cancer. In support of
this finding, a recent case–control study that investigated the
association between LINE-1 methylation and renal cell carcinoma
showed a direct association between methylation and risk of renal
cell carcinoma (Liao et al, 2011), while another study that
evaluated LINE-1 methylation status in normal and cancerous
cells found out sporadic hypermethylation of LINE-1 loci in cancer
cells (Phokaew et al, 2008). Although nonlinear associations
between exposures and cancer are still uncommonly reported, yet
there are recent examples indicating that this more complex
relationship is also possible and a fact. Studies that have shown
U-shaped risk patterns similar to that observed in this study relate
to studies analyzing the association between pancreatic cancer and
folate, a primary methyl group donor for DNA methylation
modifications (Chuang et al, 2011), telomere length and pancreatic
cancer (Skinner et al, 2012), serum sex hormones and prostate
cancer (Salonia et al, 2012) and serum vitamin D and prostate
cancer (Tuohimaa et al, 2004). Recent studies have demonstrated
that methylation blocks the initiation of transcription of repetitive
DNA sequences such as LINE-1 and Alu elements, while at the
same time allowing transcriptional elongation of the host gene,
suggesting that methylation at repetitive sequences might have dual
functions in addition to silencing repetitive sequences depending
on the location and context of these regions (Jones, 2012).
To our knowledge, the present study is the first to show a
significant interaction between LINE-1 methylation and SNPs in
PEMT gene on the risk of bladder cancer. There is no available data
on bladder cancer risk and PEMT polymorphisms. However, a
population-based study identified a SNP in a promoter region of
PEMT to be associated with increased risk of breast cancer
(Xu et al, 2008). PEMT is located within the Smith–Magenis syndrome
region on chromosome 17 and encodes for a transmembrane
protein involved in important cellular processes, including choline
and lipid metabolism, insulin sensitivity and homocysteine levels
(Vance et al, 2007). PEMT methylates, using SAM as a substrate,
phosphatidylethanolamine to phosphatidylcholine, which accounts
for 95% of total choline pool in tissues (Vance et al, 2007; Ueland,
2011). Evidence suggest that phosphatidylcholine metabolism
could be involved in malignant transformations (Glunde et al,
2011). Experimental studies have demonstrated altered choline
metabolism in tumours, mediated by transcription factors (signal-
ing pathways) associated with oncogenesis such as hypoxia-
inducible factors 1 and by the RAS and PI3K/AKT pathways
(Glunde et al, 2011). It has been known that these pathways are
Table 1. Distribution of characteristics of cases and controls with LINE-1
methylation data in the SBC/EPICURO study
Cases,
n (%)
(n¼952)
Controls,
n (%)
(n¼892) P-value
Age (years), median (IQR) 68 (13) 66 (13) o0.001a
Sex
Men 826 (86.8) 792 (88.8) 0.2b
Women 126 (13.2) 100 (11.2)
Region
Barcelona 162 (17.0) 168 (18.8) 0.7b
Valles 148 (15.5) 135 (15.1)
Elche 72 (7.6) 73 (8.2)
Tenerife 173 (18.2) 145 (16.3)
Asturias 397 (41.7) 371 (41.6)
Smoking status
Never smoker 137 (14.5) 255 (28.7) o0.001b
Occasional smoker 34 (3.6) 66 (7.4)
Former smoker 376 (39.7) 329 (37.0)
Current smoker 399 (42.2) 239 (26.9)
Missing 6 3
Subphenotypes
Non-muscle invasive
Low-risk non-muscle invasive 523 (57.3) –
High-risk non-muscle invasive 185 (20.3) –
Muscle invasive 204 (22.4) –
Missing 40 –
Tumour stage
Ta 590 (64.7) –
Tis 6 (0.7) –
T1 112 (12.3) –
T2 111 (12.2) –
T3 47 (5.1) –
T4 46 (5.0) –
Missing 40 –
Grade
PUNLMP 42 (4.6) –
G1 257 (28.2) –
G2 267 (29.3) –
G3 346 (37.9) –
Missing 40 –
Abbreviations: IQR¼ interquartile range; PUNLMP¼papillary urothelial neoplam of low
malignant potential; Tis¼ flat carcinoma in situ (CIS).
aMann–Whitney U-test’s P-value.
bw2-test’s P-value.
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constitutively activated in the majority of bladder tumours, namely
low-grade non-muscle-invasive papillary tumours, which account
for 70–80% of bladder cancer cases (Wu, 2005; Lopez-Knowles
et al, 2006). On the other hand, upon oxidation choline gives rise
to betaine, which promotes remethylation of homocysteine to
methionine affecting the concentration of SAM (Ueland, 2011).
Table 2. Association between LINE-1 methylation and bladder cancer risk in the SBC/EPICURO study
LINE-1 methylation (tertiles) Cases, n Controls, n Crude OR 95% CI P-value
T1 (o56.68%) 337 298 1.29 (1.02–1.62) 0.03
T2 (56.68–o58.65%) 261 297 1.00 Reference
T3 (X58.65%) 354 297 1.36 (1.08–1.70) 0.008
LINE-1 methylation (tertiles) Cases, n Controls, n ORa 95% CI P-value
T1 (o56.68%) 335 296 1.26 (0.99–1.60) 0.06
T2 (56.68–o58.65%) 260 297 1.00 Reference
T3 (X58.65%) 351 296 1.33 (1.05–1.69) 0.02
Abbreviations: CI¼ confidence interval; OR¼odds ratio.
aModel adjusted for age, sex, region and smoking status.
Table 3. Interaction between LINE-1 methylation and single-nucleotide polymorphisms in phosphatidylethanolamine N-methyltransferase (PEMT) in the
SBC/EPICURO study
rs2124344[CC], PEMT, intron rs2124344 [CT-TT], PEMT, intron
LINE-1
methylation
(tertiles) Cases Controls OR 95% CI P
LINE-1
methylation
(tertiles) Cases Controls OR 95% CI P
P
interactiona
Corrected
P interactionb
T1 (o56.68%) 148 112 2.26 1.52–3.36 5.2 10 5 T1 (o56.68%) 179 177 0.89 0.65–1.21 0.4 1.5 10 5 0.01
T2 (56.68–o58.65%) 76 132 1 (Ref.) T2 (56.68–o58.65%) 181 160 1 (Ref.)
T3 (X58.65%) 158 107 2.69 1.80–4.00 1.2 10 6 T3 (X58.65%) 184 183 0.86 0.63–1.18 0.4
rs7215833[CC], PEMT, flanking 50UTR rs7215833[CT-TT], PEMT, flanking 50UTR
LINE-1 methylation
(tertiles)
Cases Controls OR 95% CI P
LINE-1 methylation
(tertiles)
Cases Controls OR 95% CI P
P
interactiona
Corrected
P interactionb
T1 (o56.68%) 155 119 2.13 1.44–3.14 0.0002 T1 (o56.68%) 172 171 0.89 0.65–1.23 0.5 3.6 10 5 0.02
T2 (56.68–o58.65%) 77 131 1 (Ref.) T2 (56.68–o58.65%) 180 161 1 (Ref.)
T3 (X58.65%) 155 101 2.62 1.76–3.91 2.4106 T3 (X58.65%) 187 189 0.87 0.64–1.19 0.4
rs4646340[AA], PEMT, intronc rs4646340 [AG-GG], PEMT, intron
LINE-1
methylation
(tertiles) Cases Controls OR 95% CI P
LINE-1
methylation
(tertiles) Cases Controls OR 95% CI P
P
interactiona
Corrected
P interactionb
T1 (o56.68%) 153 116 2.13 1.43–3.16 0.0002 T1 (o56.68%) 174 174 0.92 0.67–1.25 0.6 3.8 10 5 0.02
T2 (56.68–o58.65%) 75 126 1 (Ref.) T2 (56.68–o58.65%) 182 166 1 (Ref.)
T3 (X58.65%) 156 99 2.69 1.79–4.04 1.810 6 T3 (X58.65%) 186 191 0.88 0.65–1.19 0.4
rs4646350[CC], PEMT,intron rs4646350[CT-TT], PEMT,intron
LINE-1
methylation
(tertiles) Cases Controls OR 95% CI P
LINE-1
methylation
(tertiles) Cases Controls OR 95% CI P
P
interactiona
Corrected
P interactionb
T1 (o56.68%) 179 175 2.16 1.45–3.20 0.0001 T1 (o56.68%) 179 175 0.91 0.66–1.24 0.5 4.9 10 5 0.03
T2 (56.68–o58.65%) 181 162 1 (Ref.) T2 (56.68–o58.65%) 181 162 1 (Ref.)
T3 (X58.65%) 186 184 2.64 1.77–3.94 2.1 10 6 T3 (X58.65%) 186 184 0.88 0.65–1.20 0.4
Abbreviations: CI¼ confidence interval; OR¼odds ratio; UTR¼ untranslated region. Minor allele frequency—rs2124344¼ 0.36, rs7215833¼ 0.36, rs4646340¼ 0.37, rs4646350¼ 0.36 and
rs46341¼ 0.37. All models are adjusted for age, sex, region and smoking status (never, occasional, former and current smoker).
aUncorrected likelihood ratio test’s P-value.
bLikelihood ratio test’s P-value corrected for multiple testing using permutation test.
crs4646341 was in perfect linkage disequilibrium with rs4646340 (r2¼ 1.0, D’¼ 1.0) and the corrected P-value for interaction of this single-nucleotide polymorphism was 0.037.
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Therefore, polymorphisms in PEMT could directly affect the one-
carbon metabolism pathway and impair DNA methylation. The
five SNPs are located in flanking 50UTR and intron of PEMT
(Figure 1). Alternatively, we cannot rule out these associations
could be due to chance.
Unlike the previous studies where linear associations were
observed between LINE-1 methylation and cancer risk, in this study
increased risk of bladder cancer at both extremes of LINE-1
methylation was observed. The risk pattern differences with the other
studies could be explained by the possibility of the present study to
further characterise the risk pattern due to its larger sample size as
well as differences in methods used to quantify DNA methylation.
A recent meta-analysis of LINE-1 methylation and bladder cancer
found a significant heterogeneity in assays used to quantify
methylation (Woo and Kim, 2012). That same analysis also identified
significant heterogeneity among studies. It should be noted that
LINE-1 methylation levels in the current study population
(mean¼ 59.2%) were significantly different from those in the
previous two studies on bladder cancer risk and LINE-1 methylation,
which reported mean methylation levels of 79.6% (Wilhelm et al,
2010) and 81.9% (Cash et al, 2012). This difference is not surprising
and probably results from the fact that distinct CpG sites were
analysed. On the other hand, the differences could perhaps be
explained by geographic dissimilarities resulting in differential
exposure to environmental factors, including diet, or genetic
background and stochastic factors present in these populations.
The limitations of this study include the fact that blood samples
were collected at the time of interviews, before initiation of
treatment. Some individuals were not included in the present
analyses owing to the lack of LINE-1 methylation data; however,
there was no relevant difference in selected characteristics except
age (among controls) and sex (among cases and controls) between
those with and without that data (Supplementary Table S7). To
minimise the potential bias, all the models were adjusted for age,
sex as well as region and smoking status. DNA methylation is
tissue specific, and it could be affected by cell type. To evaluate
whether there is a difference in methylation level among blood cell
types, LINE-1 methylation level was quantified in DNA separately
isolated from neutrophils and lymphocytes, the most abundant
white blood cell types. There was no difference in LINE-1
methylation level between these cell types, which is in agreement
with studies that found significant correlations between LINE-1
methylation assays of different blood cell types among healthy
individuals (Wu et al, 2011) as well as bladder cancer patients (van
Bemmel et al, 2012). However, the study on bladder cancer patients
also showed lack of correlation between global DNA methylation in
the blood and bladder tissue (van Bemmel et al, 2012), while another
study showed LINE-1 methylation to be consistent from tissue to
tissue, indicating that tissue heterogeneity might not be associated
with LINE-1 methylation levels (Choi et al, 2009).
The study has also important strengths. First is the sample size:
to the best of our knowledge, this is the first large study to
investigate the association between LINE-1 methylation and
bladder cancer risk (and any other cancer type). Second, the study
integrates a wide range of information, including epidemiological,
clinical, environmental and genetic data. Third, the method used to
Figure 1. Linkage disequilibrium plot for single-nucleotide polymorphisms (SNPs) in phosphatidylethanolamine N-methyltransferase (PEMT),
including the five SNPs analysed in the current study.
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quantify LINE-1 methylation has been shown to be a good surrogate
marker of global DNA methylation (Yang et al, 2004). Determining
DNA methylation levels by pyrosequencing provides reproducible
and accurate results (Tost and Gut, 2007; Laird, 2010).
In conclusion, this study showed that both low and high levels of
global DNA methylation may be associated with increased risk of
bladder cancer and that this risk can be markedly modified by PEMT.
Taken together, the results suggest that DNA methylation and the
one-carbon metabolism pathway have a relevant role in the
development of bladder cancer. Global DNA methylation may have
a more complex association with bladder cancer than previously
thought. In addition, the findings suggest that DNA methylation
measured in peripheral blood cells could be further explored to be
used as a susceptibility marker for bladder cancer risk. Nevertheless,
further studies in large and independent populations are required.
ACKNOWLEDGEMENTS
We acknowledge the coordinators, field and administrative
workers, technicians and patients of the Spanish Bladder
Cancer/EPICURO Study. This work was supported by the
Association for International Cancer Research (grant number
09-0780); Fondo de Investigacio´n Sanitaria, Spain (grant numbers
00/0745, PI051436, PI061614, G03/174); Red Tema´tica de
Investigacio´n Cooperativa en Ca´ncer (grant number RD12/
0036/0050-RTICC), Spain; European Commission (grant numbers
EU-FP7-HEALTH-F2-2008-201663-UROMOL; EU-FP7-HEALTH-
F2-2008-201333-DECanBio); Fundacio´n Cientı´fica de la AECC,
Spain; US National Institutes of Health (grant number USA-NIH-
RO1-CA089715); and the Intramural Research Program of the
Division of Cancer Epidemiology and Genetics, National Cancer
Institute at the National Institutes of Health, USA.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
REFERENCES
Amaral AF, Porta M, Silverman DT, Milne RL, Kogevinas M, Rothman N,
Cantor KP, Jackson BP, Pumarega JA, Lopez T, Carrato A, Guarner L,
Real FX, Malats N (2011) Pancreatic cancer risk and levels of trace
elements. Gut 61(11): 1583–1588.
Cash HL, Tao L, Yuan JM, Marsit CJ, Houseman EA, Xiang YB, Gao YT,
Nelson HH, Kelsey KT (2012) LINE-1 hypomethylation is associated with
bladder cancer risk among nonsmoking Chinese. Int J Cancer 130(5):
1151–1159.
Choi SH, Worswick S, Byun HM, Shear T, Soussa JC, Wolff EM, Douer D,
Garcia-Manero G, Liang G, Yang AS (2009) Changes in DNA methylation
of tandem DNA repeats are different from interspersed repeats in cancer.
Int J Cancer 125(3): 723–729.
Chuang SC, Stolzenberg-Solomon R, Ueland PM, Vollset SE, Midttun O,
Olsen A, Tjonneland A, Overvad K, Boutron-Ruault MC, Morois S,
Clavel-Chapelon F, Teucher B, Kaaks R, Weikert C, Boeing H,
Trichopoulou A, Benetou V, Naska A, Jenab M, Slimani N, Romieu I,
Michaud DS, Palli D, Sieri S, Panico S, Sacerdote C, Tumino R, Skeie G,
Duell EJ, Rodriguez L, Molina-Montes E, Huerta JM, Larranaga N,
Gurrea AB, Johansen D, Manjer J, Ye W, Sund M, Peeters PH, Jeurnink S,
Wareham N, Khaw KT, Crowe F, Riboli E, Bueno-de-Mesquita B, Vineis P
(2011) A U-shaped relationship between plasma folate and pancreatic
cancer risk in the European Prospective Investigation into Cancer and
Nutrition. Eur J Cancer 47(12): 1808–1816.
Estecio MR, Gharibyan V, Shen L, Ibrahim AE, Doshi K, He R, Jelinek J,
Yang AS, Yan PS, Huang TH, Tajara EH, Issa JP (2007) LINE-1
hypomethylation in cancer is highly variable and inversely correlated with
microsatellite instability. PLoS One 2(5): e399.
Esteller M (2008) Epigenetics in cancer. N Engl J Med 358(11): 1148–1159.
Florl AR, Schulz WA (2008) Chromosomal instability in bladder cancer.
Arch Toxicol 82(3): 173–182.
Garcia-Closas M, Malats N, Real FX, Yeager M, Welch R, Silverman D,
Kogevinas M, Dosemeci M, Figueroa J, Chatterjee N, Tardon A, Serra C,
Carrato A, Garcia-Closas R, Murta-Nascimento C, Rothman N, Chanock SJ
(2007a) Large-scale evaluation of candidate genes identifies associations
between VEGF polymorphisms and bladder cancer risk. PLoS Genet 3(2): e29.
Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M,
Hein DW, Tardon A, Serra C, Carrato A, Garcia-Closas R, Lloreta J,
Castano-Vinyals G, Yeager M, Welch R, Chanock S, Chatterjee N,
Wacholder S, Samanic C, Tora M, Fernandez F, Real FX, Rothman N
(2005) NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder
cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
Lancet 366(9486): 649–659.
Garcia-Closas M, Ye Y, Rothman N, Figueroa JD, Malats N, Dinney CP,
Chatterjee N, Prokunina-Olsson L, Wang Z, Lin J, Real FX, Jacobs KB,
Baris D, Thun M, De Vivo I, Albanes D, Purdue MP, Kogevinas M,
Kamat AM, Lerner SP, Grossman HB, Gu J, Pu X, Hutchinson A, Fu YP,
Burdett L, Yeager M, Tang W, Tardon A, Serra C, Carrato A,
Garcia-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR,
Schned A, Andriole Jr G, Grubb 3rd R, Black A, Jacobs EJ, Diver WR,
Gapstur SM, Weinstein SJ, Virtamo J, Hunter DJ, Caporaso N, Landi MT,
Fraumeni Jr JF, Silverman DT, Chanock SJ, Wu X (2011) A genome-wide
association study of bladder cancer identifies a new susceptibility locus
within SLC14A1, a urea transporter gene on chromosome 18q12.3.
Hum Mol Genet 20(21): 4282–4289.
Garcia-Closas R, Garcia-Closas M, Kogevinas M, Malats N, Silverman D,
Serra C, Tardon A, Carrato A, Castano-Vinyals G, Dosemeci M, Moore L,
Rothman N, Sinha R (2007b) Food, nutrient and heterocyclic amine intake
and the risk of bladder cancer. Eur J Cancer 43(11): 1731–1740.
Glunde K, Bhujwalla ZM, Ronen SM (2011) Choline metabolism in malignant
transformation. Nat Rev Cancer 11(12): 835–848.
Hopkins WA, Staub BP, Baionno JA, Jackson BP, Roe JH, Ford NB (2004)
Trophic and maternal transfer of selenium in brown house snakes
(Lamprophis fuliginosus). Ecotoxicol Environ Saf 58(3): 285–293.
Izarzugaza MI, Ardanaz E, Chirlaque MD, Font C, Ameijide A, Linares C
(2010) Tobacco-related tumours of the lung, bladder and larynx: changes
in Spain. Ann Oncol 21(Suppl 3): iii52–iii60.
Jones PA (2012) Functions of DNA methylation: islands, start sites, gene
bodies and beyond. Nat Rev Genet 13(7): 484–492.
Jurgens B, Schmitz-Drager BJ, Schulz WA (1996) Hypomethylation of L1
LINE sequences prevailing in human urothelial carcinoma. Cancer Res
56(24): 5698–5703.
Laird PW (2010) Principles and challenges of genomewide DNA methylation
analysis. Nat Rev Genet 11(3): 191–203.
Lee YL, Xu X, Wallenstein S, Chen J (2009) Gene expression profiles of the
one-carbon metabolism pathway. J Genet Genomics 36(5): 277–282.
Liao LM, Brennan P, van Bemmel DM, Zaridze D, Matveev V, Janout V,
Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D,
Rothman N, Boffetta P, Chow WH, Moore LE (2011) LINE-1 methylation
levels in leukocyte DNA and risk of renal cell cancer. PLoS One 6(11):
e27361.
Lopez-Knowles E, Hernandez S, Malats N, Kogevinas M, Lloreta J, Carrato A,
Tardon A, Serra C, Real FX (2006) PIK3CA mutations are an early genetic
alteration associated with FGFR3 mutations in superficial papillary
bladder tumors. Cancer Res 66(15): 7401–7404.
Lotan Y, Svatek RS, Malats N (2008) Screening for bladder cancer: a
perspective. World J Urol 26(1): 13–18.
Moore LE, Malats N, Rothman N, Real FX, Kogevinas M, Karami S,
Garcia-Closas R, Silverman D, Chanock S, Welch R, Tardon A, Serra C,
Carrato A, Dosemeci M, Garcia-Closas M (2007) Polymorphisms in
one-carbon metabolism and trans-sulfuration pathway genes and
susceptibility to bladder cancer. Int J Cancer 120(11): 2452–2458.
Moore LE, Pfeiffer RM, Poscablo C, Real FX, Kogevinas M, Silverman D,
Garcia-Closas R, Chanock S, Tardon A, Serra C, Carrato A, Dosemeci M,
Garcia-Closas M, Esteller M, Fraga M, Rothman N, Malats N (2008)
Genomic DNA hypomethylation as a biomarker for bladder cancer
susceptibility in the Spanish Bladder Cancer Study: a case-control study.
Lancet Oncol 9(4): 359–366.
Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, Steineck G, Kogevinas M,
Real FX, Malats N (2007) Epidemiology of urinary bladder cancer: from
tumor development to patient’s death. World J Urol 25(3): 285–295.
Global DNA methylation and bladder cancer risk BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.67 2129
Parkin DM (2008) The global burden of urinary bladder cancer. Scand J Urol
Nephrol Suppl (218): 12–20.
Phokaew C, Kowudtitham S, Subbalekha K, Shuangshoti S, Mutirangura A
(2008) LINE-1 methylation patterns of different loci in normal and
cancerous cells. Nucleic Acids Res 36(17): 5704–5712.
Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD,
Real FX, Van Den Berg D, Matullo G, Baris D, Thun M, Kiemeney LA,
Vineis P, De Vivo I, Albanes D, Purdue MP, Rafnar T, Hildebrandt MA,
Kiltie AE, Cussenot O, Golka K, Kumar R, Taylor JA, Mayordomo JI,
Jacobs KB, Kogevinas M, Hutchinson A, Wang Z, Fu YP,
Prokunina-Olsson L, Burdett L, Yeager M, Wheeler W, Tardon A, Serra C,
Carrato A, Garcia-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR,
Schned A, Andriole Jr. G, Grubb 3rd R, Black A, Jacobs EJ, Diver WR,
Gapstur SM, Weinstein SJ, Virtamo J, Cortessis VK, Gago-Dominguez M,
Pike MC, Stern MC, Yuan JM, Hunter DJ, McGrath M, Dinney CP,
Czerniak B, Chen M, Yang H, Vermeulen SH, Aben KK, Witjes JA,
Makkinje RR, Sulem P, Besenbacher S, Stefansson K, Riboli E, Brennan P,
Panico S, Navarro C, Allen NE, Bueno-de-Mesquita HB, Trichopoulos D,
Caporaso N, Landi MT, Canzian F, Ljungberg B, Tjonneland A,
Clavel-Chapelon F, Bishop DT, Teo MT, Knowles MA, Guarrera S,
Polidoro S, Ricceri F, Sacerdote C, Allione A, Cancel-Tassin G, Selinski S,
Hengstler JG, Dietrich H, Fletcher T, Rudnai P, Gurzau E, Koppova K,
Bolick SC, Godfrey A, Xu Z, Sanz-Velez JI, D Garcı´a-Prats M, Sanchez M,
Valdivia G, Porru S, Benhamou S, Hoover RN, Fraumeni Jr JF,
Silverman DT, Chanock SJ (2010) A multi-stage genome-wide association
study of bladder cancer identifies multiple susceptibility loci. Nat Genet
42(11): 978–984.
Royston P, Sauerbrei W (2007) Multivariable modeling with cubic regression
splines: a principled approach. Stata J 7(1): 45–70.
Salonia A, Abdollah F, Capitanio U, Suardi N, Briganti A, Gallina A,
Colombo R, Ferrari M, Castagna G, Rigatti P, Montorsi F (2012)
Serum sex steroids depict a nonlinear u-shaped association with high-
risk prostate cancer at radical prostatectomy. Clin Cancer Res 18(13):
3648–3657.
Samanic C, Kogevinas M, Dosemeci M, Malats N, Real FX, Garcia-Closas M,
Serra C, Carrato A, Garcia-Closas R, Sala M, Lloreta J, Tardon A,
Rothman N, Silverman DT (2006) Smoking and bladder cancer in Spain:
effects of tobacco type, timing, environmental tobacco smoke, and gender.
Cancer Epidemiol Biomarkers Prev 15(7): 1348–1354.
Skinner HG, Gangnon RE, Litzelman K, Johnson RA, Chari ST, Petersen GM,
Boardman LA (2012) Telomere length and pancreatic cancer: a case-control
study. Cancer Epidemiol Biomarkers Prev 21(11): 2095–2100.
Taby R, Issa JP (2010) Cancer epigenetics. CA Cancer J Clin 60(6): 376–392.
Tost J, Gut IG (2007) DNA methylation analysis by pyrosequencing.
Nat Protoc 2(9): 2265–2275.
Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G,
Stattin P, Harvei S, Hakulinen T, Luostarinen T, Dillner J, Lehtinen M,
Hakama M (2004) Both high and low levels of blood vitamin D are
associated with a higher prostate cancer risk: a longitudinal, nested
case-control study in the Nordic countries. Int J Cancer 108(1): 104–108.
Ueland PM (2011) Choline and betaine in health and disease. J Inherit Metab
Dis 34(1): 3–15.
Ulrey CL, Liu L, Andrews LG, Tollefsbol TO (2005) The impact of
metabolism on DNA methylation. Hum Mol Genet 14(Spec No 1):
R139–R147.
van Bemmel D, Lenz P, Liao LM, Baris D, Sternberg LR, Warner AC,
Johnson AT, Jones MA, Kida M, Schwenn M, Schned A, Silverman DT,
Rothman N, Moore LE (2012) Correlation of LINE-1 methylation levels in
patient matched buffy coat, serum, buccal cell and bladder tumor tissue
DNA samples. Cancer Epidemiol Biomarkers Prev 21(7): 1143–1148.
Vance DE, Li Z, Jacobs RL (2007) Hepatic phosphatidylethanolamine
N-methyltransferase, unexpected roles in animal biochemistry and
physiology. J Biol Chem 282(46): 33237–33241.
Volanis D, Kadiyska T, Galanis A, Delakas D, Logotheti S, Zoumpourlis V
(2010) Environmental factors and genetic susceptibility promote urinary
bladder cancer. Toxicol Lett 193(2): 131–137.
Wilhelm CS, Kelsey KT, Butler R, Plaza S, Gagne L, Zens MS, Andrew AS,
Morris S, Nelson HH, Schned AR, Karagas MR, Marsit CJ (2010)
Implications of LINE1 methylation for bladder cancer risk in women.
Clin Cancer Res 16(5): 1682–1689.
Wolff EM, Byun HM, Han HF, Sharma S, Nichols PW, Siegmund KD,
Yang AS, Jones PA, Liang G (2010) Hypomethylation of a LINE-1
promoter activates an alternate transcript of the MET oncogene in
bladders with cancer. PLoS Genet 6(4): e1000917.
Woo HD, Kim J (2012) Global DNA hypomethylation in peripheral blood
leukocytes as a biomarker for cancer risk: a meta-analysis. PLoS One 7(4):
e34615.
Wu HC, Delgado-Cruzata L, Flom JD, Kappil M, Ferris JS, Liao Y, Santella RM,
Terry MB (2011) Global methylation profiles in DNA from different blood
cell types. Epigenetics 6(1): 76–85.
Wu XR (2005) Urothelial tumorigenesis: a tale of divergent pathways.
Nat Rev Cancer 5(9): 713–725.
Xu X, Gammon MD, Zeisel SH, Lee YL, Wetmur JG, Teitelbaum SL,
Bradshaw PT, Neugut AI, Santella RM, Chen J (2008) Choline metabolism
and risk of breast cancer in a population-based study. FASEB J 22(6):
2045–2052.
Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP (2004) A simple
method for estimating global DNA methylation using bisulfite PCR of
repetitive DNA elements. Nucleic Acids Res 32(3): e38.
This work is published under the standard license to publish agree-
ment. After 12 months the work will become freely available and
the license terms will switch to a Creative Commons Attribution-
NonCommercial-Share Alike 3.0 Unported License.
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)
ANNEX 1
Spanish Bladder Cancer/EPICURO Study Investigators
Institut Municipal d’Investigacio´ Me`dica, Universitat Pompeu
Fabra, Barcelona—Coordinating Center (M Kogevinas, N Malats,
F X Real, M Sala, G Castan˜o, M Tora`, D Puente, C Villanueva,
C Murta-Nascimento, J Fortuny, E Lo´pez, S Herna´ndez,
R Jaramillo, G Vellalta, L Palencia, F Ferma´ndez, A Amoro´s,
A Alfaro, G Carretero); Hospital del Mar, Universitat Auto`noma
de Barcelona, Barcelona (J Lloreta, S Serrano, L Ferrer,
A Gelabert, J Carles, O Bielsa, K Villadiego); Hospital Germans
Trias i Pujol, Badalona, Barcelona (L Cecchini, J M Saladie´,
L Ibarz); Hospital de Sant Boi, Sant Boi de Llobregat,
Barcelona (M Ce´spedes); Consorci Hospitalari Parc Taulı´,
Sabadell (C Serra, D Garcı´a, J Pujadas, R Hernando, A Cabezuelo,
C Abad, A Prera, J Prat); Centre Hospitalari i Cardiolo`gic,
Manresa, Barcelona (M Dome`nech, J Badal, J Malet); Hospital
Universitario de Canarias, La Laguna, Tenerife (R Garcı´a-Closas, J
Rodrı´guez de Vera, A I Martı´n); Hospital Universitario Nuestra
Sen˜ora de la Candelaria, Tenerife (J Tan˜o, F Ca´ceres); Hospital
General Universitario de Elche, Universidad Miguel Herna´ndez,
Elche, Alicante (A Carrato, F Garcı´a-Lo´pez, M Ull, A Teruel,
E Andrada, A Bustos, A Castillejo, J L Soto); Universidad de
Oviedo, Oviedo, Asturias (A Tardo´n); Hospital San Agustı´n,
Avile´s, Asturias (J L Guate, J M Lanzas, J Velasco); Hospital
Central Covadonga, Oviedo, Asturias (J M Ferna´ndez, J J
Rodrı´guez, A Herrero); Hospital Central General, Oviedo, Asturias
(R Abascal, C Manzano, T Miralles); Hospital de Cabuen˜es, Gijo´n,
Asturias (M Rivas, M Arguelles); Hospital de Jove, Gijo´n, Asturias
(M Dı´az, J Sa´nchez, O Gonza´lez); Hospital de Cruz Roja, Gijo´n,
Asturias (A Mateos, V Frade); Hospital Alvarez-Buylla (Mieres,
Asturias): P Muntan˜ola, C Pravia; Hospital Jarrio, Coan˜a, Asturias
(A M Huescar, F. Huergo); and Hospital Carmen y Severo Ochoa,
Cangas, Asturias (J Mosquera).
BRITISH JOURNAL OF CANCER Global DNA methylation and bladder cancer risk
2130 www.bjcancer.com |DOI:10.1038/bjc.2014.67
